BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32146536)

  • 1. Cost-effectiveness analyses of interventions to improve osteoporosis care in France.
    Martin J; Viprey M; Castagne B; Barral M; Chapurlat R; Julien C; Serrier H; Schott AM
    Arch Osteoporos; 2020 Mar; 15(1):42. PubMed ID: 32146536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
    Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
    Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of two inexpensive postfracture osteoporosis interventions: results of a randomized trial.
    Majumdar SR; Lier DA; Leslie WD
    J Clin Endocrinol Metab; 2013 May; 98(5):1991-2000. PubMed ID: 23596140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture.
    Majumdar SR; Lier DA; Rowe BH; Russell AS; McAlister FA; Maksymowych WP; Hanley DA; Morrish DW; Johnson JA
    Osteoporos Int; 2011 Jun; 22(6):1799-808. PubMed ID: 20878389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of a fracture liaison service--a real-world evaluation after 6 years of service provision.
    Yong JH; Masucci L; Hoch JS; Sujic R; Beaton D
    Osteoporos Int; 2016 Jan; 27(1):231-40. PubMed ID: 26275439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M; Reginster JY
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.
    Su Y; Lai FTT; Yip BHK; Leung JCS; Kwok TCY
    Osteoporos Int; 2018 Aug; 29(8):1793-1805. PubMed ID: 29774400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom.
    Svedbom A; Hadji P; Hernlund E; Thoren R; McCloskey E; Stad R; Stollenwerk B
    Osteoporos Int; 2019 Sep; 30(9):1745-1754. PubMed ID: 31270592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of osteoporosis interventions for 'incidental' vertebral fractures.
    Majumdar SR; Lier DA; McAlister FA; Rowe BH; Siminoski K; Hanley DA; Russell AS; Johnson JA
    Am J Med; 2013 Feb; 126(2):169.e9-17. PubMed ID: 23331449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
    Yoshizawa T; Nishino T; Okubo I; Yamazaki M
    Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.
    Hiligsmann M; Ben Sedrine W; Bruyère O; Reginster JY
    Osteoporos Int; 2013 Aug; 24(8):2291-300. PubMed ID: 23371359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Osteoporosis Interventions to Improve Quality of Care After Upper Extremity Fracture: Results From a Randomized Trial (C-STOP Trial).
    Majumdar SR; Lier DA; McAlister FA; Johnson JA; Rowe BH; Beaupre LA
    J Bone Miner Res; 2019 Jul; 34(7):1220-1228. PubMed ID: 30779861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial.
    Majumdar SR; Johnson JA; Lier DA; Russell AS; Hanley DA; Blitz S; Steiner IP; Maksymowych WP; Morrish DW; Holroyd BR; Rowe BH
    Osteoporos Int; 2007 Mar; 18(3):261-70. PubMed ID: 17086470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effective osteoporosis treatment thresholds in Greece.
    Makras P; Athanasakis K; Boubouchairopoulou N; Rizou S; Anastasilakis AD; Kyriopoulos J; Lyritis GP
    Osteoporos Int; 2015 Jul; 26(7):1949-57. PubMed ID: 25740208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
    Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
    JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A health economic simulation model for the clinical management of osteoporosis.
    Jonsson E; Hansson-Hedblom A; Ljunggren Ö; Åkesson K; Spångeus A; Kanis JA; Borgström F
    Osteoporos Int; 2018 Mar; 29(3):545-555. PubMed ID: 29196775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of hip fracture prevention with vitamin D supplementation: a Markov micro-simulation model applied to the French population over 65 years old without previous hip fracture.
    Zarca K; Durand-Zaleski I; Roux C; Souberbielle JC; Schott AM; Thomas T; Fardellone P; Benhamou CL
    Osteoporos Int; 2014 Jun; 25(6):1797-806. PubMed ID: 24691648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis.
    Söreskog E; Borgström F; Lindberg I; Ström O; Willems D; Libanati C; Kanis JA; Stollenwerk B; Charokopou M
    Osteoporos Int; 2021 Jul; 32(7):1301-1311. PubMed ID: 33411005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
    Kreck S; Klaus J; Leidl R; von Tirpitz C; Konnopka A; Matschinger H; König HH
    Pharmacoeconomics; 2008; 26(4):311-28. PubMed ID: 18370566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.